

CHEMISTRY A European Journal



Accepted Article

Title: Emissive synthetic cofactors: A highly responsive NAD+ analogue reveals biomolecular recognition features

Authors: Jonas Feldmann, Yao Li, and Yitzhak Tor

This manuscript has been accepted after peer review and appears as an Accepted Article online prior to editing, proofing, and formal publication of the final Version of Record (VoR). This work is currently citable by using the Digital Object Identifier (DOI) given below. The VoR will be published online in Early View as soon as possible and may be different to this Accepted Article as a result of editing. Readers should obtain the VoR from the journal website shown below when it is published to ensure accuracy of information. The authors are responsible for the content of this Accepted Article.

To be cited as: Chem. Eur. J. 10.1002/chem.201805520

Link to VoR: http://dx.doi.org/10.1002/chem.201805520

Supported by ACES



Emissive synthetic cofactors: A highly responsive NAD⁺ analogue reveals biomolecular recognition features

Jonas Feldmann^[a, b], Yao Li^[a], and Yitzhak Tor*^[a]

Abstract: Apart from its vital function as a redox cofactor. nicotinamide adenine dinucleotide (**NAD**⁺) has emerged as a crucial substrate for **NAD**⁺-consuming enzymes, including poly(ADPribosvl)transferase 1 (PARP1) and CD38/CD157. Their association with severe diseases, such as cancer. Alzheimer's disease, and depressions, necessitates the development of new analytical tools based on traceable NAD⁺ surrogates. Here we describe the synthesis, photophysics and biochemical utilization of an emissive, thieno[3,4-d]pyrimidine-based NAD⁺ surrogate, termed NthAD⁺. Its preparation was accomplished by enzymatic conversion of synthetic thATP via nicotinamide mononucleotide adenylyltransferase 1 (NMNAT1). The new NAD⁺ analogue possesses useful photophysical features including red-shifted absorption and emission maxima as well as a relatively high quantum yield. Serving as a versatile substrate, NthAD⁺ is reduced by alcohol dehydrogenase (ADH) to NthADH and affords thADP-ribose (thADPr) upon hydrolysis by **NAD**⁺-nucleosidase (NADase). Furthermore, **N**th**AD**⁺ can be engaged in Cholera toxin A (CTA)-catalyzed mono(thADPribosyl)ation but is found incapable in promoting PARP1-mediated poly(thADP-ribosyl)ation. Due to its high photophysical responsiveness, NthAD⁺ is suited for spectroscopic real-time monitoring. Intriguingly, and as an N7-lacking NAD⁺ surrogate, the thieno-based cofactor shows reduced compatibility (i.e. functional similarity compared to native NAD⁺) relative to its isothiazolo-based analogue. The distinct tolerance, displayed by diverse NAD⁺ producing and consuming enzymes, suggest unique biological recognition features and dependency on the purine's N7 moiety, which is found to be of importance, if not essential, for PARP1mediated reactions.

Introduction

The most prominent role of nicotinamide adenine dinucleotide (**NAD**⁺, Scheme 1) is as a redox cofactor in regulating central metabolic pathways by catalyzing a variety of oxidoreductasemediated processes.^[1] More recently, but as significantly, **NAD**⁺ has been found to act as a substrate for multiple enzymes that catalyze glycosidic cleavage of the nicotinamide moiety and release an ADP-ribose (**ADPr**) moiety, which is then transferred onto acceptor molecules, such as proteins, DNA, and smaller metabolites.^[2–10]

[a]	Y. Li, Prof. Yitzhak Tor
	Department of Chemistry and Biochemistry
	University of California, San Diego
	La Jolla, CA 92093-0358 (USA)
	E-mail: ytor@ucsd.edu
[b]	J. Feldmann
	Department of Chemistry
	Ludwig-Maximilians-Universität München
	Butenandtstr. 5-13, 81377 Munich (Germany)

Supporting information for this article is given via a link at the end of the document.



Figure 1. Structural formula of native NAD⁺ and emissive analogues $N^{tz}AD^{+}$ and $N^{th}AD^{+}$. Purine *N*7 moieties are highlighted in blue.

In this regard, three major classes of NAD⁺-consuming enzymes are commonly identified, including sirtuins, (ADPribose)polymerases and cyclic ADP-ribose synthases.[2-10,11] Malfunction or dysregulation of these enzymes have been found to disrupt cellular NAD⁺ homoeostasis and, as a consequence, could cause severe diseases such as cancer, diabetics, atherosclerosis, Alzheimer's disease, depressions, and neurodegeneration.[2-10,12]

To restore cellular NAD⁺ levels and thus counteract detrimental pathways, inhibition of **NAD**⁺-consuming enzymes, most notably poly(ADP-ribose)polymerase 1 (PARP1) and CD38/CD157, has shown promise.^[13-17,18] The significance of **NAD**⁺-mediated processes necessitates the development of novel tools and probes to facilitate biophysical analyses and the fabrication of effective discovery assays. Radioactive,^[19] clickable,^[20,21] isotopically-labelled,^[22] and fluorescent^[23,24] **NAD**⁺ surrogates have been developed. Design of the latter has employed the incorporation of emissive adenosine analogues. including the perturbing $1, N^6$ -ethenoadenosine and 8-(pyrrol-2vl)adenosine.^[23,24] To exploit the safety and sensitivity of fluorescence-based tools, which closely reflect the native system, both isomorphicity and isofunctionality of a synthetic analogue have to be attained by reducing structural and functional perturbations, respectively, thus ensuring maximum biological compatibility. Concurrently, photophysical responsiveness towards environmental and structural changes is required to enable real-time spectroscopic monitoring.^[25]

In the last few years, a new generation of emissive nucleoside analogues has been developed based on a novel set of purine-mimicking scaffolds: thieno[3,4-*d*]pyrimidines^[26] and isothiazolo[4,3-*d*]pyrimidines.^[27] Such isomorphic analogues open a spectral window into processes involving nucleosides and nucleotides derivatives, which is otherwise inaccessible with the native counterparts.^[28,29] A red shifted absorption and useful fluorescence features in the visible range, which are non-existent for the native counterparts, facilitate the fabrication of biochemical and discovery assays with minimal spectral interference by the native chromophores.^[28,29]



Scheme 1. Synthesis of **N**th**AD**. Reagents and conditions: (a) i) TMP, POCI₃, 0 °C; ii) tris(tetrabutylammonium) hydrogen pyrophosphate, Bu₃N, DMF, 0 °C, 6.1% over two steps; (b) Tris-HCl pH 7.8, KCl, NaCl, MgCl₂, NMN, PPase, NMNAT1, *dd*H₂O, 37 °C, 81%. NMN, β-nicotinamide mononucleotide; PPase Pyrophosphatase; NMNAT1, mononucleotide adenylyltransferase 1.

While the thieno[3,4-d]pyrimidine family of nucleosides displays outstanding emission features, the isothiazolo[4,3-d]pyrimidinebased analogues, while somewhat less emissive, provide enhanced isomorphicity and isofunctionality.^[30,31] Having access to both purine analogues, offers, however, a unique opportunity to assess biomolecular recognition features using sensitive fluorescence-based tools. Comparing the native NAD⁺ to its emissive analogues, NthAD⁺ and its single-site mutant N^{tz}AD⁺ (Figure 1), can provide mechanistic insight into the biomolecular contacts mediated via the imidazole ring, and particularly its N7 nitrogen. While the purines' N7 moiety is known to be crucial for a variety of biological recognition events, including enzymesubstrate binding (e.g., adenosine-adenosine deaminase),[32] Hoogsteen base pairing,^[33] and G-quadruplex formation,^[34] its significance in NAD⁺-dependent processes is poorly explored and largely limited to crystallographic studies.[35-39] Unlike N7deaza-NAD⁺, which has been employed as an N7-lacking substrate, we hypothesized that NthAD⁺ will likely be emissive and responsive, and thus will likely facilitate fluorescence spectroscopic monitoring of enzymatic activities in real time.^[37-40] Furthermore, its red-shifted absorption spectra, compared to the native NAD⁺, facilitates selective excitation and opens a spectral window that is unavailable for the native cofactor. Herein, we therefore describe the synthesis and photophysics of NthAD⁺ (Figure 1), an NAD⁺ analogue containing the isomorphic and highly emissive thieno[3,4-d]pyrimidine core. We report its enzymatic synthesis by NMNAT1, and its responsiveness to ADH-mediated reduction to NthADH, NADase-catalyzed hydrolysis yielding thADP-ribose (thADPr) and consumption by (ADP-ribosyl)ating enzymes including Cholera toxin A and PARP1. Comparison with both native NAD⁺ and emissive N^{tz}AD⁺ provides insight into its putative recognition features via the basic N7 within the purine skeleton

Results and Discussion

Synthesis

The preparation of $N^{th}AD^{*}$ was accomplished in two steps starting from the previously synthesized ${}^{th}A.{}^{[26]}$ The corresponding triphosphate was first chemically synthetized and

WILEY-VCH

		<u>A.</u>		
	λ_{abs} [nm]	ε [M ⁻¹ cm ¹]	λ _{em} [nm]	Φ
A ^[a]	260	14.9 x 10 ³	310	5 x 10 ⁻⁵
^{tz} A ^[a]	338	7.8 x 10 ³	410	0.053
th A ^[a]	341	7.4 x 10 ³	420	0.21
NAD ^{+[a]}	259	16.9 x 10 ³	-	-
N ^{tz} AD ^{+[a]}	338	7.2 x 10 ³	411	0.044
N th AD ^{+[b]}	341	7.0 x 10 ³	431	0.071

[a] Previously reported values, see corresponding references.^[26,27,29,40,41] [b] ϵ determined at the end of NMNAT1-mediated conversion in relation to respective substrates, assuming complete consumption in 50 mM Tris-HCl buffer. All photophysical properties reflect the average of two independent measurements.

then enzymatically reacted with β -nicotinamide mononucleotide (NMN) using recombinant nicotinamide mononucleotide adenylyl-transferase1 (NMNAT1).^[26] This overcomes the final phosphodiester bond formation in the non-enzymatic syntheses of NAD⁺ analogues, which is commonly accomplished *via* coupling reagents (e.g., Staab's reagent) and is associated by long reaction times and low yields.^[30] The optimized enzymatic approach can be adapted to preparative scales.^[31]

Practically, th**A** was first treated with POCl₃ and trimethyl phosphate, followed by the addition of tris(tetrabutylammonium) hydrogen pyrophosphate and tributylamine to yield th**ATP** (Scheme 1).^[41] It was then treated with β-nicotinamide mononucleotide (NMN) and NMNAT1 (Tris pH 7.8, 37°C). Addition of inorganic pyrophosphatase (PPase) was required to avoid product inhibition of NMNAT1 by the released pyrophosphate. As assessed by HPLC, quantitative conversion was achieved after 2.5 h and a good isolated yield (81%) was obtained on a 1 mg scale.

Photophysical Features

To assess the basic photophysical features of $N^{th}AD^{+}$, its absorption and emission spectra were recorded and compared to the native cofactor and the previously synthesized $N^{tz}AD^{+}$ (Table 1). In comparison to NAD^{+} ($\lambda_{abs} = 259$ nm) and similarly to $N^{tz}AD^{+}$ ($\lambda_{abs} = 338$ nm), $N^{th}AD^{+}$ features a bathochromically shifted absorption maximum at $\lambda_{abs} = 341$ nm (Table 1). Notably, excitation near the absorption maximum is found to cause photo bleaching, which can be avoided by excitation at $\lambda_{ex} = 360$ nm, yielding a well-defined emission band with a maximum at 431 nm. Compared to $N^{tz}AD^{+}$ ($\Phi = 0.044$), and as initially hypothesized, $N^{th}AD^{+}$ exhibits a higher quantum yield of $\Phi = 0.071$.

WILEY-VCH

NMNAT1- and ADH-Mediated Conversion



Scheme 2. NMNAT1-mediated synthesis of native **NAD**⁺ and emissive analogues followed by ADH-mediated reduction in the presence of EtOH. Purine and derived ring systems (blue), pyridinium (purple) and 1,4-dihydropyridine (red) moieties are highlighted. Triphosphate groups are represented by PPP_i. NMN, nicotinamide mononucleotide; NMNAT1, nicotinamide mononucleotide adenylyl-transferase 1; ADH, alcohol dehydrogenase.

To evaluate the compatibility of $N^{th}AD^+$, and gain access to $N^{th}ADH$, its reduction equivalent, a sequential enzymatic conversion assay employing both *Homo sapiens* recombinant NMNAT1 and *Saccharomyces cerevisiae* alcohol dehydrogenase (ADH) was performed.^[31,42] While NMNAT1 naturally accomplishes phosphodiester bond formation between NMN and **ATP** to generate **NAD**^{+,[43]} ADH reduces **NAD**⁺ to

NADH by oxidizing ethanol to acetaldehyde (Scheme 2).

To compare the performance of thATP, ^{tz}ATP and native ATP, the conversion of each nucleotide in this coupled enzymatic process was followed by HPLC, real-time spectroscopic monitoring and steady-state emission and absorption spectroscopy. Treatment with NMN and NMNAT1 facilitated quantitative conversion of both ATP and ^{tz}ATP within 30 min and complete consumption of thATP within 100 min as assessed by HPLC (Figure 2a-c). Spectroscopic assessment highlighted the differences between the analogues. While the emission intensity decreased upon formation of both N^{tz}AD⁺ and NthAD, it remained unchanged during the formation of "fluorescently silent" **NAD**⁺ (Figure 2d–f). Notably, all substrates were reduced rapidly within a few minutes in the presence of ethanol and ADH. Spectroscopically, reduction of native NAD⁺ shows an increase in emission intensity, whereas decreasing emission intensity was observed upon reduction of both ^{tz}A- and thA-based synthetic emissive cofactors. Steady state spectra recorded before treatment and after each enzymatic conversion (Figures 2q-i) reveal phosphodiester bond formation to have little or no effect on the absorption spectra of neither substrate but show a diminished fluorescence for both synthetic cofactors. In all cases, ADH-mediated cofactor reduction results into an increased optical density between 300 and 400 nm, accompanied by a further decrease in emission. This two-step decrease, however, is found to be distinct for each emissive cofactor: While the initial emission level of thATP is diminished by 70% upon NthAD⁺ formation, ADH-mediated reduction causes an additional

decrease

of

after the second reaction.

contrast, the conversion

^{tz}ATP shows a diminution of

40% after the first and 30%

only

8%.

In

of



Figure 2. Monitoring of the NMNAT1-mediated synthesis and ADH-catalyzed reduction of native **NAD**^{*} and emissive analogues. Top row: HPLC traces of (a) **ATP**, (b) ^{tz}**ATP** and (c) th**ATP** (blue each), corresponding **NAD**^{*} species (purple) and their reduced forms (red) monitored before conversion, 30 min (th**ATP**: 60 min) after treatment with NMNAT1 and 30 min after the addition of ADH at $\lambda_{abs} = 260$, 330 and 340 nm, respectively. Mid row: Normalized emission intensity signals over time recorded for the conversion of (d) **ATP** at 465 nm ($\lambda_{ex} = 335$), (e) ^{tz}**ATP** at 410 nm ($\lambda_{ex} = 330$) and (f) th**ATP** at 410 nm ($\lambda_{ex} = 360$) before (blue) and upon (purple) treatment with NMNAT1 and after the addition of ADH (red). Bottom row: Steady state absorption (dashed lines) and emission (solid lines) spectra for the conversion of (g) **ATP** ($\lambda_{ex} = 335$), (h) ^{tz}**ATP** ($\lambda_{ex} = 330$) and (i) th**ATP**: ($\lambda_{ex} = 360$) recorded before conversion (blue), 30 min (th**ATP**: 60 min) after treatment with NMNAT1 (purple) and 10 min (th**ATP**: 20 min) after the addition of ADH (red).

The enhanced photophysical features of the thieno-based cofactor reveal $N^{th}AD^{+}$ to be a suited fluorophore for real-time spectroscopic monitoring of NAD⁺ synthesis and reduction processes. Its high photophysical responsiveness may be attributed to intramolecular ground and excited state interactions between the modified purine surrogate and the nicotinamide moiety, interactions that have been evoked for the native cofactor but remain insufficiently explored .^[30,44] The relatively slow conversion of thATP by NMNAT1 suggests thA to be less compatible than both the native adenosine and its isothiazolobased purine analogue. We therefore suggest that the imidazole ring and especially contacts through its *N*7 nitrogen are of significance for NMNAT1–substrate recognition, although the exact contribution of the *N*7 nitrogen has not been studied in great detail and remains somewhat elusive.^[45]

NADase-Mediated Hydrolysis



Scheme 3. NADase-mediated hydrolysis of native NAD⁺ and emissive analogues, yielding corresponding ADP-ribose (ADPr) species. Pyridinium moiety (purple) and anomeric hydroxy group (yellow) are highlighted. NADase, NAD⁺ nucleosidase.

To take advantage of the intramolecular photophysical interaction between the nicotineamide moiety and the emissive purine surrogate and to evaluate enzymatic cleavage of NthAD⁺, an NADase-based assay was applied.^[30] This hydrolase catalyzes the glycosidic cleavage of the nicotinamide moiety and release of ADP-ribose (ADPr, Scheme 3), which naturally serves as a secondary messenger and is involved in intramolecular calcium signaling.^[46]

Both emissive cofactors were treated with porcine brain NADase. Quantitative conversion was observed after 30 min for $N^{tz}AD^{+}$ and 120 min for $N^{th}AD^{+}$, and was accompanied by the formation of $t^{tz}ADPr$ and $t^{th}ADPr$, respectively (Figures 3a,b). Assuming similar extinction coefficients for the starting materials and products, $t^{tz}ADPr$ was obtained in a 2.8-fold higher amount compared to $t^{th}ADPr$. The latter was isolated, identified and characterized by steady state spectroscopy to reveal bathochromically shifted absorption and emission maxima ($\lambda_{abs} = 340 \text{ nm}$, $\lambda_{em} = 431 \text{ nm}$; Figure S1). Real-time spectroscopic monitoring of $N^{tz}AD^{+}$ hydrolysis showed an increasing emission signal within 25 min (Figure 3c). In contrast, a four-time longer period was required for quantitative $N^{th}AD^{+}$ hydrolysis (Figure 3d). The corresponding steady state spectra reveal enhanced optical density and emission intensity within the visible range



Figure 3. Monitoring of the NADase-mediated hydrolysis of emissive NAD⁺ analogues. Top row: HPLC traces of (a) $N^{tz}AD^{+}$ (purple) and $^{tz}ADPR$ (yellow) monitored before and 30 min after treatment with NMNAT1 at $\lambda_{abs} = 330$ nm; (b) $N^{th}AD^{+}$ (purple) and $^{th}ADPR$ (yellow) monitored before and 120 min after treatment with NMNAT1 at $\lambda_{abs} = 340$ nm. Mid row: Normalized emission intensity signals over time recorded for the conversion of (c) $N^{tz}AD^{+}$ at 410 nm ($\lambda_{ex} = 330$) and (d) $N^{th}AD^{+}$ at 410 nm ($\lambda_{ex} = 360$) before (purple) and upon (yellow) treatment with NADase. Bottom row: Steady state absorption (dashed lines) and emission (solid lines) spectra for the hydrolysis of (e) $N^{tz}AD^{+}$ ($\lambda_{ex} = 330$) and (f) $N^{th}AD^{-}$ ($\lambda_{ex} = 360$) recorded before (purple) treatment and 25 min ($N^{th}AD$: 120 min) after the addition of NADase (yellow).

(Figures 3e,f), where treatment of $N^{tz}AD^{+}$ and $N^{th}AD^{+}$ with NADase yielded a 40% and 60% enhancement, respectively,upon enzymatic hydrolysis.

The findings presented above reveal $N^{th}AD^{+}$ to be highly photophysically responsive towards glycosidic cleavage and the associated enhanced emission supports the nicotinamidemediated quenching effects. The comparatively slow hydrolysis of $N^{th}AD^{+}$ compared to $N^{tz}AD^{+}$ indicates, however, somewhat reduced substrate compatibility for NADase and, as before, suggests the purine's *N*7 moiety to be involved in enzyme – substrate interactions in this enzymatic pocket.

CTA-Mediated Mono(ADP-ribosyl)ation

To further explore the compatibility of the emissive $N^{th}AD^{+}$ and gain insight into more complex and challenging modification processes, enzymatic conversions by the Cholera toxin were examined. As a hexameric protein complex, this *Vibrio cholerae* toxin consists of five receptor-binding B subunits (CTB) and an enzymatically active A subunit (CTA).^[47] The latter catalyzes the glycosidic cleavage of NAD⁺ and formation of ADP-ribose

WILEY-VCH

(ADPr), which can be transferred onto arginine (Arg) side chains and other guanidine-containing derivatives.^[48] This process, known as mono(ADP-ribosyl)ation, classifies CTA as a mono(ADP-ribosyl)transferase. Furthermore, CTA is found to modify and intrinsically inhibit the guanine nucleotide-binding G_S alpha subunit (G_{-S}) of heterotrimeric G_S Proteins, which causes severe dehydration and other cholera-associated symptoms.^[49]



Scheme 4. CTA-mediated conversion of native **NAD**⁺ and emissive analogues, including (a) hydrolysis and (b) mono(ADP-ribosyl)ation of agmatine. Anomeric hydroxy group (yellow), pyridinium (purple) and agmatine (green) moieties are highlighted. CTA, cholera toxin A; Agm, agmatine.

While Arg-containing proteins serve as major intracellular CTA targets, the less bulky and easily detectable agmatine (Agm), is commonly employed as an Arg surrogate for CTA-based *in vitro* assays.^[50] By utilizing this approach, we recently found CTA to consume $N^{tz}AD^{+}$ and form mono(^{tz}ADP -ribosyl)ated agmatine ($^{tz}ADPr$ -Agm, Scheme 4). To compare the suitability of $N^{th}AD^{+}$, solutions of the cofactors and Agm were

treated with CTA. This cost-intensive assay and small reaction volumes, however, disfavored real-time spectroscopic monitoring and necessitated sequential records of steady state spectra. Samples were thus taken after 0, 20, 50, 90, and 180 min and analyzed both spectroscopically and by HPLC. Conversion of native NAD⁺ was exclusively monitored *via* HPLC.

Upon treatment with CTA, quantitative conversion was detected by HPCL after 90 min for NAD⁺ and 180 min for both N^{tz}AD⁺ and NthAD⁺ (Figures 4a-c). In addition, thADPr-Agm was isolated. identified and spectroscopically characterized, revealing bathochromically shifted absorption and emission maxima (λ_{abs} = 341 nm, λ_{em} = 425 nm, Figure S3). Along with the formation of Agm adducts, hydrolysis to the corresponding ADPr analogues was observed as a major side reaction in all three cases. Assuming similar extinction coefficients for the starting materials and Agm aducts, the by-product/product ratios amount to 0.20, 0.37, and 0.59 for the native-, isothiazolo-, and thienobased cofactors, respectively. Furthermore, treatment of either fluorescent cofactor with CTA causes a significant increase in emission intensity, as assessed by steady state spectroscopy (Figures 4e,f). CTA-mediated conversion of NthAD⁺ yielded an emission enhancement of 360%, whereas conversion of NtrAD+ yielded a 70% increase only.

To compare the chromatographic and spectroscopic monitoring methods, the integrated HPLC product peak areas and emission intensities were plotted against time. The HPLC-derived plots reveal a faster formation of **ADPr-Agm** compared to both ^{tz}**ADPr-Agm** and th**ADPr-Agm**, of which the latter is the slowest to form (Figure 4d, solid lines). The normalized emission intensities (Figure 4d, dashed lines) confirm the kinetics observed for **N**th**AD**⁺ conversion but suggest **N**^{tz}**AD**⁺ to convert slightly slower than indicated by HPLC. The slight deviation between spectroscopically and HPLC-derived kinetic



Figure 4. Monitoring of the CTA-mediated mono(ADP-ribosyl)ation accomplished by **NAD**⁺ and emissive analogues. Top row: HPLC traces of (a) **NAD**⁺, (b) **N**^{tz}**AD**⁺ and (c) **N**th**AD**⁺ (purple), agmatine adducts (green) and hydrolysis products (yellow) monitored after 0, 20, 50, 90 and 180 min at $\lambda_{bbs} = 260$, 330 and 340 nm, respectively. Bottom row: (d) Normalized emission intensity signals (dashed lines) and HPLC peak area (solid lines) over time for the conversion of **NAD**⁺ (black) and **N**th**AD**⁺ (purple); Error bars refer to standard deviations of the normalized mean. Steady state absorption (dashed lines) and emission (solid lines) spectra for the conversion of (e) **N**^{tz}**AD**⁺ ($\lambda_{ex} = 330$) and (f) **N**th**AD**⁺ ($\lambda_{ex} = 360$) recorded after 0 min (purple), 20 min (violet), 50 min (blue), 90 min (green) and 180 min (bright green).

measurements has been seen before^[30] and could be attributed to the formation of by- or decomposition products that affect the overall emission intensity. Despite these minor limitations, NthAD⁺ can be used powerful as а fluorophore due to its high spectroscopic

responsiveness upon mono(thADP-ribosyl)ation.

Its slow conversion, as well as the excessive formation of th**ADPr**, reveal, however, a poorer recognition by CTA compared to both $N^{th}AD^+$ and NAD^+ . These findings further support substrate recognition via the purine's *N*7 nitrogen. Although X-ray-based studies of Fieldhouse et al.

WILEY-VCH

have revealed multiple intermolecular interactions between **NAD**⁺ and CTA in detail, the involvement of the *N*7 nitrogen has remained crystallographically elusive.^[36]

PARP1-Mediated Poly(ADP-ribosyl)ation

In contrast to CTA, which acts as a mono(ADPribose)transferase, PARP1 mediates poly(ADP-ribosyl)ation by transferring multiple ADPr units to itself or other target proteins, forming poly(ADP-ribose) linkages (pADPr, Scheme 5). Depending on its chain structure and length, such posttranslational modifications can affect the activity and localization of associated proteins and their non-covalent interaction with other binding partners.^[51] Hence, PARP1 functions as a regulatory key enzyme, which is involved in DNA damage response, metabolic regulation and transcriptional activation processes, among others.^[52] Association with severe diseases makes PARP1 an attractive therapeutic target, which is driving the development of novel inhibitors and treatment of breast, prostate, and ovarian cancer, among others.^[13–17]

Given that PARP1 can act as both the enzyme and the target, we studied its auto-poly(ADP-ribosyl)ation using all cofactors and calf thymus DNA as an activating agent.^[21,53,54] Accordingly, a solution of PARP1 was treated with calf thymus DNA before inducing the reaction with $N^{tz}AD^+$ or $N^{th}AD^+$. Positive controls included native NAD^+ and negative controls included reaction mixtures without the cofactors. The conversion was then monitored at different time points both spectroscopically and via SDS-PAGE. To facilitate adequate detection and differentiation between modified and unmodified PARP1, western blotting based on anti-PARP1 and anti-pADPr antibodies was performed.^[21]



Initial attempts to spectroscopically monitor this transformation in real time did not reveal any change in emission intensity, neither upon treatment with N^{tz}AD⁺ nor with NthAD⁺. The Coomassiestained SDS-PAGE (Figure 5a) did show, however, PARP1-related bands to decrease in intensity over time for both cofactors. This decrease is most striking upon adding NAD⁺ and still substantial upon N^{tz}AD⁺ treatment, whereas addition of NthAD⁺ shows only little effect. Modified PARP1, in contrast, remains undetectable by Coomassie staining and necessitated western blotting for further analysis. The respective blot (Figure 5b) confirms a diminishing concentration of unmodified PARP1 (green channel) upon addition of NAD⁺ or N^{tz}AD⁺, respectively.

Visualization of anti-pADPr (blue channel) confirms the formation of **pADPr**- and **p**^{tz}**ADPr**-modified PARP1, respectively, which is manifested in smeared higher MW bands. **NAD**⁺- induced formation of auto-modified PARP1 is detected as early as after 2 min and found to increase for 60 min. A reduced amount of **pADPR**-modified PARP1 was detected after 180 min. In comparison, **p**^{tz}**ADPr**-related bands arise at lower MW, are less intense and show a regression already after 10 min. In contrast, no **p**th**ADPr** was detected upon treatment with **N**th**AD**⁺.

important consideration when assessing An the observations articulated above is the biochemical specificity of the antibodies, particularly the anti-pADPr one. Designed to bind native pADPr, anti-pADPr is known to interact with 3-4 ADPr units of linear pADPr, which can be associated with proteins both covalently and non-covalently.^[55,56] Oligomers consisting of 10 ADPr units or less are not efficiently captured, whereas polymers of > 20 **ADPr** units facilitate proper binding as revealed by competitive binding assays.^[55] Beside these known limitations, neither the exact epitopes of anti-pADPr nor its interaction with p^{tz}ADPr or pthADPr, respectively, are known.^[57]Hence, a reduced or even no affinity of anti-pADPr towards synthetic pADPr analogues cannot be excluded but will be neglected in the following evaluation.



Figure 5. (a) Coomassie stained SDS-PAGE and (b) western blot of PARP1mediated auto-poly(ADP-ribosyl)ation reactions in presence of native NAD^{+} and emissive analogues, respectively. Marker (lane 1); untreated sample (negative control, lane 2); treatment with NAD^{+} (positive control, lanes 3-6), $N^{tz}AD^{+}$ (lanes 7-10) and $N^{th}AD^{+}$ (lanes 11-13); samples were taken after 2, 10, 60 and 180 min, respectively.

To further analyze the observations discussed above, two opposite and kinetically divergent processes have to be considered: First, the increasing amount of modified PARP1 as well as the shift to higher MW reveal an ongoing polymerization reaction upon treatment with **NAD**⁺ and **N**^{tz}**AD**⁺. Secondly, the subsequent regression of modified PARP1 indicates decomposition and cleavage of the **pADPr**–protein linkages, which are known to be fragile ($t_{1/2} < 1$ h, pH 7.5)^[58,59] Notably, this decomposition process is favored in the presence of nicotinamide, which is released upon poly(ADP-ribosyl)ation. Previous studies under similar conditions (pH 8.0, 20 µg rat liver PARP, 100 nM NAD⁺, 23 °C) showed a regressing amount of **pADPr**-modified PARP after 50 min, which is consistent with the kinetics obtained for **NAD**⁺-induced PARP1 auto-modification.^[59]

correspondingly modified PARP1 suggest reduced compatibility, which could reflect less effective oligomerization or faster degradation of the shorter oligomers formed. On the other hand, the apparent absence of **p**th**ADPr**-modified PARP1 suggests poly(thADP-ribosyl)ation to be severely limited with **N**th**AD**⁺, if not impossible, and illustrates its diminished recognition as a PARP1 substrate. This is supported by crystallographic studies of **NAD**⁺-bound PARP1, which illustrate hydrophobic interactions between isoleucine (Ile872) and the adenosine's imidazole ring. Additionally, the purines N7 nitrogen is proposed to interact with the protein via an aspartic acid residue.^[60] Such enzyme–substrate interactions, while possible with **N^{tr}AD**⁺ cannot be accommodated by **NthAD**⁺, the thiopheno-based system lacking a basic N at the corresponding position.

Conclusions

This study set out to prepare NthAD⁺, an N7-lacking, thieno[3,4d pyrimidine-based **NAD⁺** surrogate, and assess its utility for monitoring **NAD**⁺-dependent reactions by spectroscopic means. Towards this end, we employed recombinant NMNAT1 that facilitates the preparative scale synthesis of NthAD⁺ from the emissive thATP. When compared to our previously developed analogue $N^{tz}AD^{+}$ (λ_{abs} = 338 nm, λ_{em} = 411 nm, Φ = 0.044), NthAD⁺ shows improved photophysical features including redshifted absorption and emission maxima (λ_{abs} = 341 nm, λ_{em} = 431 nm) and a higher emission quantum yield ($\Phi = 0.071$). Moreover, NthAD⁺ serves as a viable substrate for ADHmediated reduction affording NthADH, NADase-catalyzed hydrolysis yielding thADPr and CTA-mediated mono(ADPribosyl)ation.. Photophysical analysis revealed NthAD⁺ to be substantially more responsive towards enzymatic conversions than its isothiazolo-based analogue and thus suited as a fluorescent probe for their spectroscopic real-time monitoring. Spectroscopic and HPLC-based analyses found NthAD⁺ to be less isofunctional than both NAD⁺ and N^{tz}AD⁺, which is manifested in lower conversion rates or increased by-product formation. When assessing PARP1-mediated auto-poly(ADPribosyl)ation, no conversion was observed upon treatment with NthAD⁺ at all, whereas N^{tz}AD⁺ is converted successfully — if only to a lower extent compared to its native cofactor, indicating an inherent PARP1-N7 dependency. These studies demonstrate the utility of both $N^{tz}AD^{+}$ and $N^{th}AD^{+}$, particularly when used side by side, for investigating biomolecular recognition features that involve purine N7 interactions. Even though being guenched within pADPr, both emissive analogues can be easily employed to monitor enzymatic reactions including NAD⁺ formation, oxidation/reduction, hydrolysis, and, potentially, mono(ADPribosyl)ation in real time.

Experimental Section

Synthesis of thATP

WILEY-VCH

A suspension of thA (50 mg, 0.18 mmol, 1.0 eq) in trimethyl phosphate (1.8 mL) was treated with POCI₃ (41 µL, 0.44 mmol, 2.5 eq.) at 0 °C under stirring. After 1 h stirring at 0 °C, additional POCl₃ (41 µL, 0.44 mmol, 2.5 eq.) was added and the suspension was stirred at 0 °C for another 2 h. After treatment with tris(tetrabutylammonium) hydrogen pyrophosphate (164 mg, 0.88 mmol, 5.0 eq) dissolved in dry DMF (1.8 mL), tributyl amine (0.21 mL, 0.88 mmol, 5.0 eq) was added drop-wise and the reaction mixture was stirred at 0 °C for 2 h. The reaction mixture was quenched with ice-cold 0.05 M TEAB (5. 0 mL), stirred at 0 °C for 15 min and washed with EtOAc (10 mL). After extracting the organic phase with 0.05 M TEAB (3 \times 5 mL), the aqueous phases were combined and concentrated in vacuo. The crude product was purified via ion exchange chromatography (Sephadex DEAE A25 column; 0.05 M → 0.5 M TEAB; 4 °C). After concentration in vacuo and lyophilization, the resulting solid was dissolved in ddH2O (1.00 mL) and purified via HPLC (70 µL injections, method see SI). Lyophilization of the collected fraction afforded a white solid of thATP (0.011 mmol, 6.1 %), which was used without further purification. ¹H-NMR (300 MHz, D_2O): δ (ppm) = 8.55 (s, 1H), 8.22 (s, 1H), 5.44 (d, J = 7.43 Hz, 1H), 4.42 (dd, J = 5.10, 3.11 Hz, 1H), 4.35 (dd, J = 7.43, 5.10 Hz, 1H), 4.30 (m, 1H), 4.22 (m, 2H); ³¹P-NMR (202 MHz, D₂O): δ (ppm) = -9.92 (d, J = 20.0 Hz), -10.83 (d, J = 19.5 Hz), -22.57 (m); ESI-HRMS [C11H16N3O13S-H⁺] calculated 521.9544, found 521.9536.

Synthesis of NthAD

A solution of Tris (50 mM), KCI (50 mM), NaCI (50 mM), MgCl₂ (12 mM), th **ATP** (1.5 mM), NMN (2.0 mM) and PPase (10 U) in *dd*H₂O (1.50 mL) was left for equilibration at 37 °C for 5 min. After addition of NMNAT1 (Novus Biologicals, 0.42 U^[60]), the reaction mixture was gently mixed and left for 2.5 h at 37 °C. The reaction was monitored *via* HPCL (method see SI) and stopped by freezing the mixture to -78 °C. The reaction mixture was concentrated to a volume of 0.3 mL by lyophilization. Purification *via* HPLC (100 µL injections, method see SI) and subsequent lyophilization afforded a white solid of NthAD (1.82 mM, 81 %). ¹H-NMR (300 MHz, D₂O): δ (ppm) = 9.30 (s, 1H), 9.10 (d, *J* = 6.19 Hz, 1H), 8.76 (d, *J* = 8.20 Hz, 1H), 8.28 (s, 1H), 8.14 (dd, *J* = 7.89, 6.46 Hz, 1H), 8.00 (s, 1H), 4.53 (d, *J* = 2.48 Hz, 1H), 4.46 (t, *J* = 5.23 Hz, 1H), 4.41 (m, 2H), 4.36 (m, 2H), 4.26 (m, 1H), 4.21 (m, 1H), 4.14 (m, 1H); ³¹P-NMR (202 MHz, D₂O): δ (ppm) = -10.63 (d, *J* = 18.73 Hz), -11.07 (d, *J* = 19.91 Hz); ESI-HRMS [C₂₂H₂₉N₅O₁₄P₂S-H⁺] calculated 678.0678, found 678.0679.

Steady State Absorption and Emission Spectroscopy

Steady state absorption spectra were measured on a Shimadzu UV-2450 spectrophotometer setting the slit at 1 nm and using a resolution of 0.5 nm. Steady state emission spectra were measured on a Horiba Fluoromax-4 setting both the excitation and the emission slits at 3 nm, the resolution at 1 nm and the integration time at 0.1 s. Both instruments were equipped with a thermostat-controlled ethylene glycol-water bath fitted to specially designed cuvette holders and the temperature was kept at 25. 0 ± 0.1 °C or 37.0 ± 0.1 °C, respectively. Native, ^{tz}A-, and thA-based probes were excited at 335, 330, and 360 nm, respectively. All spectra were corrected for the blank. Further assay-dependent specificities can be found in the SI.

Spectroscopic Real-Time Monitoring

Enzymatic conversion was followed by monitoring the emission intensity at a fixed wavelength as function of time. Emission was measured on a Horiba Fluoromax-4 equipped with a cuvette holder with a built-in stirring system, setting both the excitation and emission slits at 3 nm and taking a point at regular time intervals. The temperature was kept at 25.0 \pm

0.1 °C or 37.0 \pm 0.1 °C, respectively. Emission was monitored at 410 nm (λ_{ex} = 360 nm), 410 nm (λ_{ex} = 330 nm) and 465 nm (λ_{ex} = 335 nm) for th ATP, tz ATP, and ATP, respectively. Further assay-dependent specificities can be found in the SI.

NMNAT1- and ADH-Mediated Conversion

In a 125 μ L cuvette, buffer containing Tris-HCl (50 mM, pH 7.8), NaCl (50 mM), KCl (50 mM), MgCl₂ (12 mM), NMN (15 μ M), PPase (0.3 U), EtOH (17 μ M), and th**ATP**, ^{tz}ATP, or ATP (15 μ M) was added to set up a total reaction volume of 500 μ L. The solution was left to stabilize at 37.0 ± 0.1 °C for 30 minutes before NMNAT1 (14 mU) was added. The mixture was promptly mixed and left at 37.0 ± 0.1 °C for 6000 s (th**ATP**) or 1800 s (^{tz}ATP, ATP), respectively. To start the second reaction, the mixture was treated with ADH (5 μ L, 58 U / μ M substrate), promptly mixed, and left at 37.0 ± 0.1 °C for 600 s (th**ATP**), respectively. All reactions were done in duplicates.

NADase-Mediated Hydrolysis

In a 3 mL cuvette equipped with a stirring bar, buffer containing Tris-HCl (50 mM, pH 7.8), NaCl (50 mM), KCl (50 mM), and NthAD⁺ or N^{tz}AD⁺ (7.5 μ M) was added to set up a final reaction volume of 3 mL. The solution was left to stabilize at 25.0 ± 0.1 °C for 30 min before an aliquot of suspended NADase (30 mU) was added. The suspension was promptly mixed and left at 25.0 ± 0.1 °C for 6300 s (NthAD⁺) or 1500 s (N^{tz}AD⁺), respectively. All reactions were done in duplicates..

CTA-Mediated Mono(ADP-ribosyl)ation

In a 600 µL sterilized conical vial, buffer containing potassium phosphate (pH 7.2; 160 mM), DTT (20 mM), agmatine sulfate (15 mM), MgCl₂ (20 mM), ovalbumine (4 g/L) and **NAD**⁺, **N**th**AD**⁺ or **N**^{tz}**AD**⁺ (7.5 µM) was added to set up a final reaction volume of 25.5 µL. The solution was left to stir at 25.0 ± 0.1 °C for 5 minutes to equilibrate. To start the reaction, CTA (255 µg) is added. All reactions were done in duplicates.

PARP1-Mediated Poly(ADP-ribosyl)ation

In a 600 µL sterilized conical vial, 4× buffer (30 µL) containing (Tris-HCl pH 8.0, 400 mM), MgCl₂ (40 mM), DTT (4 mM) and calf thymus DNA (15 mg/L) was added and left to stabilize at 37 °C for 3 min. Subsequently, PARP1 (4.1µL, 150 nM final conc.) was added, the solution was gently mixed and left at 37 °C for another 3 min to activate PARP1. After treatment with **N**th**AD**⁺, **N**^{tz}**AD**⁺, or **NAD**⁺ (60 µL, 500 µM final conc.), the mixture was gently mixed and left at 37 °C for 180 min. All reactions were done in duplicates.

SDS-PAGE

For sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), samples of 9 μ L were taken after given time points. The reaction was stopped by treating the samples with 4× loading bu er and subsequent heating at 95 °C for 5 min. In order to avoid decomposition of modified PARP1, samples were immediately frozen at -78 °C and stored at -20 °C. Prior resolution, reaction samples were thawed and loaded onto 8.0% SDS gels according to Laemmli.^[61] Electrophoresis was performed at 100 V for 30 min, then 150 V for 30 min and 200 V for 60 min in SDS running buffer.

Coomassie Staining

After resolving the reaction mixtures *via* SDS-PAGE, the gel was rinsed in *dd*H₂O once, immersed in staining solution (0.15% Coomassie Brilliant Blue R-250, 45% MeOH, 10% acetic acid in *dd*H₂O), microwaved for 50 s and shaken for 20 min at RT. After rinsing with *dd*H₂O, the gel was covered with destaining solution (5.0% MeOH, 7.5% acetic acid in *dd*H₂O), microwaved for 50 s and shaken for 24 h at RT. The destaining solution was replaced frequently. To estimate molecular weights, PageRuler Plus Prestained Protein Ladder (Thermo Fisher) was used as a reference.

Western Blot

After resolving the reaction mixtures via SDS-PAGE, gels were electrophoretically transferred onto a PVDF membrane (GE HealthCare) in 1× NuPAGE Transfer Buffer (ThermoFisher) + 10% MeOH at 30 V for 70 min. The membrane was blocked in Odyssey Blocking Bu er (LI-COR) at RT for 30 min under agitation. After blocking, the membrane was incubated with anti-PAR [10H] antibody (Tulip BioLabs, 10 µg/mL) in 1× TBST buffer at 4 °C o/n. The membrane was washed three times with 1× TBST buffer for 5 min each and incubated with anti-mouse IRDye 680RD antibody (LI-COR, diluted 1:15,000) at RT for 1 h. Subsequently, the membrane was washed three times with 1× TBST buffer + 0.2 % SDS for 5 min each and then three times with 1× PBS-buffer for 5 min each. The membrane was incubated with anti-PARP1 antibody (Tulip BioLabs, 1 µg/mL) in 1× TBST buffer at RT for 1 h. The membrane was washed three times with 1× TBST buffer for 5 min each and incubated with anti-chicken secondary antibody (diluted 1:15,000) at RT for 1 h. Subsequently, the membrane was washed three times with 1× TBST buffer + 0.2% SDS for 5 min each and then three times with 1× PBSbuffer for 5 min each. Finally, the membrane was stored in PBS buffer until imaged and quantitatively analyzed via Image Studio (LI-COR).

Acknowledgements

We thank the National Institutes of Health for generous support (GM 069773) and UCSD's Chemistry & Biochemistry MS Facility. We are grateful to Dr. Alexander Rovira for helpful discussions and to the DAAD and Bavarian State for supporting J.F. with the PROSA LMU scholarship.

Keywords: cofactors • NAD⁺ • spectroscopy • ADP-ribosylation • PARP1

- L. Sellés Vidal, C. L. Kelly, P. M. Mordaka, J. T. Heap, *Biochim. Biophys. Acta*. 2018, 1866, 327.
- [2] R. H. Houtkooper, C. Canto, R. J. Wanders, J. Auwerx, *Endocr. Rev.* **2010**, *31*, 194.
- [3] M. S. Cohen, P. Chang, *Nat. Chem. Biol.* **2018**, *14*, 236.
- F. Koch-Nolte (Ed.) Current Topics in Microbiology and Immunology, Vol. 384, Springer International Publishing, Cham, s 1 2015
- [5] B. Lüscher, M. Bütepage, L. Eckei, S. Krieg, P. Verheugd, B. H.
- Shilton, Chem. Rev. 2018, 118, 1092.
- [6] L. Palazzo, A. Mikoč, I. Ahel, *FEBS J* **2017**, *284*, 2932.
- [7] V. Schreiber, F. Dantzer, J.-C. Ame, G. de Murcia, *Nat. Rev. Mol. Cell Biol.* 2006, 7, 517.
- [8] H. Lin, Org. Biomol. Chem. 2007, 5, 2541.
- [9] E. Barkauskaite, G. Jankevicius, I. Ahel, *Mol. Cell.* 2015, 58, 935.
- [10] S. Michan, D. Sinclair, Biochem. J. 2007, 404, 1.
- [11] a) P. Chambon, J. D. Weill, P. Mandel, Biochem. Biophys. Res. Commun. 1963, 11, 39; b) A. de Flora, E. Zocchi, L. Guida, L.

Januscri

JOCOE

Franco, S. Bruzzone, Ann. N. Y. Acad. Sci. 2004, 1028, 176; c) S. Imai, C. M. Armstrong, M. Kaeberlein, L. Guarente, Nature 2000, 403, 795.

- [12] a) C. Cantó, K. J. Menzies, J. Auwerx, Cell Metab. 2015, 22, 31; b) Y. S. Elhassan, A. A. Philp, G. G. Lavery, J. Endocr. Soc. 2017, 1, 816; c) E. Verdin, Science 2015, 350, 1208; d) E. F. Fang, S. Lautrup, Y. Hou, T. G. Demarest, D. L. Croteau, M. P. Mattson, V. A. Bohr, Trends Mol. Med. 2017, 23, 899; e) M. C. Haigis, D. A. Sinclair, Annu. Rev. Pathol.: Mech. Dis. 2010, 5, 253; f) P. Belenky, K. L. Bogan, C. Brenner, Trends Biochem. Sci. 2007, 32, 12; g) R. H. Houtkooper, E. Pirinen, J. Auwerx, Nat. Rev. Mol. Cell Biol. 2012, 13, 225 EP -
- [13] N. V. Malyuchenko, E. Y. Kotova, O. I. Kulaeva, M. P Kirpichnikov, V. M. Studitskiy, Acta Naturae 2015, 7, 27.
- [14] K. N. Dziadkowiec, E. Gąsiorowska, E. Nowak-Markwitz, A. Jankowska, Menopause Rev. 2016, 15, 215
- N. J. Curtin, C. Szabo, Mol. Aspects. Med. 2013, 34, 1217. [15]
- [16] M. S. Drenichev, S. N. Mikhailov, Bioorg. Med. Chem. Lett. 2016, 26, 3395.
- [17] E. Wahlberg, T. Karlberg, E. Kouznetsova, N. Markova, A. Macchiarulo, A.-G. Thorsell, E. Pol, A. Frostell, T. Ekblad, D. Oencue et al., Nat. Biotechnol. 2012, 30, 283.
- [18] a) A. K. Y. Kwong, Z. Chen, H. Zhang, F. P. Leung, C. M. C. Lam, K. Y. Ting, L. Zhang, Q. Hao, L.-H. Zhang, H. C. Lee, Biochemistry 2012, 51, 555; b) H. M. Lokhorst, T. Plesner, J. P. Laubach, H. Nahi, P. Gimsing, M. Hansson, M. C. Minnema, U. Lassen, J. Krejcik, A. Palumbo et al., N. Engl. J. Med. 2015, 373, 1207; c) L. Virág, C. Szabó, Pharmacol. Rev. 2002, 54, 375.
- [19] D. B. McCormick, L. D. Wright (Eds.) Methods in Enzymology, v. 18, pt. B, Academic Press, New York, 1971.
- [20] H. Jiang, J. H. Kim, K. M. Frizzell, W. L. Kraus, H. Lin, J. Am. Chem. Soc. 2010, 132, 9363.
- [21] Y. Wang, D. Rösner, M. Grzywa, A. Marx, Angew. Chem. Int. Ed. Engl. 2014, 53, 8159.
- [22] J. Evans, T.-C. Wang, M. P. Heyes, S. P. Markey, Anal. Biochem. 2002, 306, 197.
- [23] C. Y. Lee, J. Everse, Arch. Biochem. Biophys. 1973, 157, 83.
- [24] G. Pergolizzi, J. N. Butt, R. P. Bowater, G. K. Wagner, Chem. Commun. (Camb.) 2011, 47, 12655.
- [25] R. W. Sinkeldam, Y. Tor, Org. Biomol. Chem. 2007, 5, 2523.
- D. Shin, R. W. Sinkeldam, Y. Tor, J. Am. Chem. Soc. 2011, [26] 133, 14912.
- [27] A. R. Rovira, A. Fin, Y. Tor, J. Am. Chem. Soc. 2015, 137, 14602
- [28] R. W. Sinkeldam, N. J. Greco, Y. Tor, Chem. Rev. 2010, 110, 2579.
- [29] M. Wilhelmsson, Y. Tor (Eds.) Fluorescent analogs of biomolecular building blocks. Design and applications, Wiley, Hoboken, New Jersey, 2016.
- [30] A. R. Rovira, A. Fin, Y. Tor, J. Am. Chem. Soc. 2017, 139, 15556
- [31] F. Hallé, A. Fin, A. R. Rovira, Y. Tor, Angew. Chem. Int. Ed. Engl. 2018, 57, 1087.
- [32] a) R. W. Sinkeldam, L. S. McCoy, D. Shin, Y. Tor, Angew. Chem. Int. Ed. Engl. 2013, 52, 14026; b) R. A. Mizrahi, D. Shin, R. W. Sinkeldam, K. J. Phelps, A. Fin, D. J. Tantillo, Y. Tor, P. A. Beal, Angew. Chem. Int. Ed. Engl. 2015, 54, 8713.
- [33] E. N. Nikolova, H. Zhou, F. L. Gottardo, H. S. Alvey, I. J. Kimsey, H. M. Al-Hashimi, Biopolymers 2013, 99
- [34] S. Burge, G. N. Parkinson, P. Hazel, A. K. Todd, S. Neidle, Nucleic. Acids. Res. 2006, 34, 5402.
- [35] A. Ruf, G. de Murcia, G. E. Schulz, *Biochemistry* 1998, 37,
- [36] R. J. Fieldhouse, R. Jørgensen, M. R. Lugo, A. R. Merrill, J. Biol. Chem. 2012, 287, 21176. [37] M. B. Lennon, W. Joseph, R. J. Suhadolnik, Biochem. Biophys.
- Res. Commun. 1976, 72, 530.
- [38] R. J. Suhadolnik, M. B. Lennon in Alcohol and Aldehyde Metabolizing Systems, Elsevier, 1977, pp. 123-136.

- [39] V. C. Bailey, J. K. Sethi, S. M. Fortt, A. Galione, B. V.L. Potter, Chemistry & Biology 1997, 4, 51
- F. Seela, M. Zulauf, M. Sauer, M. Deimel, HCA 2000, 83, 910. [40]
- [41] L. S. McCoy, D. Shin, Y. Tor, J. Am. Chem. Soc. 2014, 136, 15176
- [42] E. Balducci, M. Emanuelli, N. Raffaelli, S. Ruggieri, A. Amici, G. Magni, G. Orsomando, V. Polzonetti, P. Natalini, Anal. Biochem. 1995, 228, 64
- [43] M. Schweiger, K. Hennig, F. Lerner, M. Niere, M. Hirsch-Kauffmann, T. Specht, C. Weise, S. L. Oei, M. Ziegler, FEBS Lett. 2001, 492, 95.
- [44] a) T. G. Scott, R. D. Spencer, N. J. Leonard, G. Weber, J. Am. Chem. Soc. 1970, 92, 687; b) B. A. Gruber, N. J. Leonard, *Proc. Natl. Acad. Sci.* **1975**, *72*, 3966; c) R. V. Hull, P. S. Conger, R. J. Hoobler, *Biophysical Chemistry* **2001**, *90*, 9; d) M. Tanaka, K. Ohkubo, S. Fukuzumi, The journal of physical chemistry. A 2006, 110, 11214.
- [45] a) E. Werner, M. Ziegler, F. Lerner, M. Schweiger, U. Heinemann, FEBS Lett. 2002, 516, 239; b) T. Zhou, O. Kurnasov, D. R. Tomchick, D. D. Binns, N. V. Grishin, V. E. Marguez, A. L. Osterman, H. Zhang, J. Biol. Chem. 2002, 277, 13148.
- [46] H. Kim, E. L. Jacobson, M. K. Jacobson, Mol. Cell. Biochem. 1994, 138, 237
- B. D. Spangler, Microbiol. Rev. 1992, 56, 622 [47]
- J. Moss, M. Vaughan, Proc. Natl. Acad. Sci. 1978, 75, 3621. [48] [49] a) L. de Haan, T. R. Hirst, Mol. Membr. Biol. 2004, 21, 77; b) A.
- Levitzki, A. Bar-Sinai, Pharmacol. Ther. 1991, 50, 271.
- [50] G. Glowacki, R. Braren, K. Firner, M. Nissen, M. Kühl, P. Reche, F. Bazan, M. Cetkovic-Cvrlje, E. Leiter, F. Haag et al., Protein Sci. 2002, 11, 1657.
- [51] B. A. Gibson, W. L. Kraus, Nat. Rev. Mol. Cell Biol. 2012, 13, 411
- [52] a) S. A. Andrabi, G. K. E. Umanah, C. Chang, D. A. Stevens, S. S. Karuppagounder, J.-P. Gagne, G. G. Poirier, V. L. Dawson, T. M. Dawson, Proc. Natl. Acad. Sci. 2014, 111, 10209; b) P. O. Hassa, C. Buerki, C. Lombardi, R. Imhof, M. O. Hottiger, J. Biol. Chem. 2003, 278, 45145; c) B. Lupo, L. Trusolino, Biochim. Biophys. Acta 2014, 1846, 201; d) L. Piao, K. Fujioka, M. Nakakido, R. Hamamoto, Front. Biosci., Landmark Ed 2018, 23, 13; e) M. Li, X. Yu, Cancer Cell 2013, 23, 693
- [53] E. Kirsten, E. Kun, J. Mendeleyev, C. P. Ordahl, Methods in molecular biology (Clifton, N.J.) 2004, 287, 137.
- R. C. Benjamin, D. M. Gill, J. Biol. Chem. 1980, 255, 10502. [54]
- [55] H. Kawamitsu, H. Hoshino, H. Okada, M. Miwa, H. Momoi, T. Sugimura, Biochemistry 1984, 23, 3771.
- [56] a) J. Fahrer, R. Kranaster, M. Altmeyer, A. Marx, A. Bürkle, Nucleic Acids Res. 2007, 35, e143; b) J.-P. Gagné, M. Isabelle, K. S. Lo, S. Bourassa, M. J. Hendzel, V. L. Dawson, T. M. Dawson, G. G. Poirier, Nucleic. Acids. Res. 2008, 36, 6959.
- [57] C. A. Vivelo, A. K. L. Leung, Proteomics 2015, 15, 203.
- [58] a) P. M. Moyle, T. W. Muir, J. Am. Chem. Soc. 2010, 132, 15878; b) P. O. Hassa, S. S. Haenni, M. Elser, M. O. Hottiger, Microbiol. Mol. Biol. Rev. 2006, 70, 789.
- P. I. Bauer, A. Hakam, E. Kun, FEBS Lett. 1986, 195, 331. [59]
- 1 unit (U) is the amount of enzyme that catalyzes the reaction [60] of 1 µmol of substrate per minute.
- [61] U. K. Laemmli, Nature 1970, 227, 680.

WILEY-VCH

Entry for the Table of Contents

FULL PAPER

FULL PAPER



A photophysically responsive, *N*7-lacking, NAD⁺ analogue (**N**th**AD**⁺) has been enzymatically synthesized and employed to study biomolecular recognition features by real-time fluorescence monitoring. **N**th**AD**⁺ serves as a substrate for multiple NAD⁺-dependent enzymes, including ADH, NADase, CTA, and NMNAT1 but not PARP1. Poorer recognition compared to an *N*7-containing analogue (**N**^{tz}**AD**⁺) suggests key biomolecular contacts via the purine's *N*7 moiety. Jonas Feldmann,^[a, b] Yao Li,^[a] and Yitzhak Tor^{x[a]}



Emissive synthetic cofactors: A highly responsive NAD⁺ analogue reveals biomolecular recognition features